Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET
September 13, 2021 08:00 ET | Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience
September 09, 2021 08:30 ET | Brooklyn Immunotherapeutics LLC
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
August 20, 2021 16:15 ET | Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021
August 20, 2021 08:30 ET | Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
August 16, 2021 16:15 ET | Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results
August 16, 2021 07:00 ET | Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that gene editing/cell and...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
August 13, 2021 14:22 ET | Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
July 19, 2021 08:00 ET | Brooklyn Immunotherapeutics LLC
Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Today, July 19, 2021, at 4:15PM ET to Discuss the...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
July 13, 2021 08:15 ET | Brooklyn Immunotherapeutics LLC
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn logo.jpg
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
July 12, 2021 08:15 ET | Brooklyn Immunotherapeutics LLC
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that...